Unique ID issued by UMIN | UMIN000007708 |
---|---|
Receipt number | R000009083 |
Scientific Title | Evaluation of the efficacy of Symbicort turbuhaler that target patients with bronchial ashtma complicated by COPD and bronchial asthma - Evaluation of diurnal variation in peak flow - |
Date of disclosure of the study information | 2012/04/10 |
Last modified on | 2012/04/09 19:09:39 |
Evaluation of the efficacy of Symbicort turbuhaler that target patients with bronchial ashtma complicated by COPD and bronchial asthma - Evaluation of diurnal variation in peak flow -
Evaluation of the efficacy of Symbicort turbuhaler that target patients with bronchial ashtma complicated by COPD and bronchial asthma - Evaluation of diurnal variation in peak flow -
Evaluation of the efficacy of Symbicort turbuhaler that target patients with bronchial ashtma complicated by COPD and bronchial asthma - Evaluation of diurnal variation in peak flow -
Evaluation of the efficacy of Symbicort turbuhaler that target patients with bronchial ashtma complicated by COPD and bronchial asthma - Evaluation of diurnal variation in peak flow -
Japan |
bronchial asthma complicated by COPD and bronchial ashtma
Medicine in general | Pneumology |
Others
NO
We evaluate the efficacy of Symbicort turbuhaler for diurnal variation of respiratory function in patients with bronchial asthma complicated by COPD and bronchial asthma. We also examine whether Symbicort turbuhaler inhibit expiratory NO as indicator of respiratory inflammation and serum substance P as indicator of airway hyperresponsiveness.
Consider that there are some reports that Symbicort is equivalent to rapid-acting bronchodilator SABA, we examine whether bronchodilator effect of Symbicort is correlated with that of SABA by resiratory function test after those inhalation.
We eventually and comprehensively determine the phenotype that Symbicort is useful.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
Diurnal variation in PEF by Piko-1
expiratory NO
eosinophil in sputum
serum substance P
FEV1.0
FEV1.0 in five minites after inhalaton of Symbicort or Procaterol Hydrochloride
chest CT
assessment of safty
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
symbicort turbuhaler
for 2years
twice daily, 1-4 inhalation
20 | years-old | <= |
Not applicable |
Male and Female
>COPD (complicated by asthma) or asthma (unquestioned stage)
>patients who have inspiratory flow rate can be inhaled test drug
>patients who voluntary consent document was obtained after receiving a full explanation upon participation in this study and full understanding
>outpatients
>patient wiht an infection refractory to any antibiotics, or deep-seated mycoses
>hitory of hypersensitivity to test drug
100
1st name | |
Middle name | |
Last name | Koichiro Tasumi |
Graduate School of Medicine, Chiba University
Department of respirology
1-8-1 inohana, chuo-ku, chiba city, chiba prefecture
043-222-7171
1st name | |
Middle name | |
Last name | Ken Iesato |
Graduate School of Medicine, Chiba University
Department of respirology
1-8-1 inohana, chuo-ku, chiba city, chiba prefecture
043-222-7171
http://www.m.chiba-u.ac.jp/class/respir/index.html
iesato@gmail.com
Department of respirology, graduate School of Medicine, Chiba University
none
Self funding
NO
2012 | Year | 04 | Month | 10 | Day |
Unpublished
Open public recruiting
2010 | Year | 09 | Month | 21 | Day |
2011 | Year | 01 | Month | 01 | Day |
2012 | Year | 04 | Month | 09 | Day |
2012 | Year | 04 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009083